## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.99 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($1014.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Eli Lilly & Company (LLY): Buyers looking for rally between $1144.4 â€“ $1196.17**
- Source: FXStreet | 20251223T135214 | Bullish | Relevance: 100%
- Eli Lilly & Company (LLY) is expected to rally between $1144.39 and $1196.17, following its impulse wave I within the larger August-2025 rally. The Elliott Wave analysis indicates an ongoing bullish impulse sequence, with the stock trading at an All-Time High. Buyers are advised to look for pullbacks in clear 3, 7, or 11 swings corrections before resuming upside movement.

**2. Jim Cramer Says Eli Lilly's GLP-1 Pill Is "Going to Revolutionize Everything"**
- Source: Finviz | 20251223T052843 | Bullish | Relevance: 100%
- Jim Cramer highlighted Eli Lilly and Company (LLY) as a powerful drug company set to revolutionize the market with its GLP-1 pill form next year, predicting a significant stock increase. He also analyzed other top holdings of a caller, including Taiwan Semi, Microsoft, Chevron, and SL Green, offering his assessment of their diversification and potential. Cramer expressed optimism about Eli Lilly's future performance, while providing a balanced view of the other companies in the portfolio.

**3. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment**
- Source: Finviz | 20251222T083900 | Bullish | Relevance: 100%
- Eli Lilly and Company (LLY) announced updated data for its oral estrogen receptor antagonist Inluriyo, showing a 38% reduction in the risk of progression or death for advanced or metastatic breast cancer as a monotherapy. The company also revealed plans to offer single-dose vials of Zepbound at reduced prices due to an agreement with the Trump administration aimed at lowering GLP-1 medication costs. Goldman Sachs recently raised its price target for Eli Lilly to $1,145 from $951, reiterating a Buy rating on the stock.

**4. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Insider Monkey | 20251221T180815 | Bullish | Relevance: 100%
- Eli Lilly and Company (LLY) announced updated results from its Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for advanced or metastatic breast cancer, showing continued clinical benefits. The company also revealed plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, to produce synthetic and peptide medicines, including forforglipron. Eli Lilly is recognized as a strong investment, though the article suggests even greater potential in certain AI stocks.

**5. Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)**
- Source: Yahoo Finance | 20251221T154727 | Bullish | Relevance: 100%
- Eli Lilly and Company released updated Phase 3 EMBER-3 study results for Inluriyo (imlunestrant), an oral estrogen receptor antagonist, showing continued clinical benefits for patients with ER+, HER2- advanced or metastatic breast cancer. The data supports Inluriyo's role both as monotherapy and in combination with abemaciclib, demonstrating durable benefits regardless of ESR1 mutation status. The company also announced plans for a new $6 billion manufacturing facility in Huntsville, Alabama, which will produce small molecule synthetic and peptide medicines, including orforglipron for obesity.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $18559M sold (28 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Forward P/E 32.9x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $960.7B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 32.9 |
| Current P/E | 45.3 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 1.5% (minimal 5-day change). Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.54), momentum weakening. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.49% (CS: 70) | Neutral |
| RSI_14 | 63.1 | Neutral |
| MACD Histogram | -0.54 | Bearish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 1.110x | Above |
| vs SMA200 | 1.306x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1071.39
- **Stop Loss:** $1014.07 (5.4% risk)
- **Target:** $1186.03 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $21,427.80
- **Portfolio %:** 21.43%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*